Target Organs and Levels of Evidence for TR-522
Toxicology and Carcinogenesis Studies of Transplacental AZT (CASRN 30516-87-1) in Swiss (CD-1®) Mice (in utero Studies)
| Chemical (Study Title) CASRN |
Peer Review Date | Route/Exposure Levels | Study Laboratory |
|---|---|---|---|
| AZT transplacental carcinogenesis study 30516-87-1 |
12/09/2004 | In Utero AZT: 50, 100, 200, OR 300 MG/KG/DAY; 25, 25, 36, OR 46 PER GROUP |
Southern Research Institute |
Levels of Evidence
Male Mice: Clear Evidence
| Type | Organ/Tissue (Lesion) |
|---|---|
| Neoplastic Lesions |
|